WO2008123017A1 - 新規なジアミド誘導体 - Google Patents

新規なジアミド誘導体 Download PDF

Info

Publication number
WO2008123017A1
WO2008123017A1 PCT/JP2008/000506 JP2008000506W WO2008123017A1 WO 2008123017 A1 WO2008123017 A1 WO 2008123017A1 JP 2008000506 W JP2008000506 W JP 2008000506W WO 2008123017 A1 WO2008123017 A1 WO 2008123017A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
disclosed
ring
diamide derivative
formula
Prior art date
Application number
PCT/JP2008/000506
Other languages
English (en)
French (fr)
Inventor
Akiyoshi Mochizuki
Tsutomu Nagata
Hideyuki Kanno
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of WO2008123017A1 publication Critical patent/WO2008123017A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

　強力なＦＸａ阻害作用を有し、経口投与でも速やかに十分かつ持続的な抗血栓効果を示す新規な化合物を提供する。 　下記の一般式（Ｉ） ［式中、環Ａはベンゼン環を示し；Ｒ１は水素原子、ハロゲノ基等；Ｒ２はカルボキシ基、カルバモイル基等；Ｔ１は、基－Ｃ（＝Ｏ）ＮＨ－等；Ｔ２は、基－ＣＨ２－ＣＨ２－Ｃ（＝Ｏ）ＮＨ－等；Ｑ１は、テトラヒドロナフチリジニル基、テトラヒドロチアゾロピリジル基等；Ｑ２は単結合；Ｑ３はフェニル基、ピリジル基等を示す。］で表される化合物又はその薬理上許容される塩、又はこれらを有効成分として含有するＦＸａ阻害剤。
PCT/JP2008/000506 2007-03-09 2008-03-10 新規なジアミド誘導体 WO2008123017A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-059675 2007-03-09
JP2007059675A JP2010120852A (ja) 2007-03-09 2007-03-09 新規なジアミド誘導体

Publications (1)

Publication Number Publication Date
WO2008123017A1 true WO2008123017A1 (ja) 2008-10-16

Family

ID=39759243

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/JP2008/000506 WO2008123017A1 (ja) 2007-03-09 2008-03-10 新規なジアミド誘導体
PCT/JP2008/000501 WO2008111299A1 (ja) 2007-03-09 2008-03-10 新規なジアミド誘導体
PCT/JP2008/000503 WO2008111300A1 (ja) 2007-03-09 2008-03-10 新規なジアミド誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/JP2008/000501 WO2008111299A1 (ja) 2007-03-09 2008-03-10 新規なジアミド誘導体
PCT/JP2008/000503 WO2008111300A1 (ja) 2007-03-09 2008-03-10 新規なジアミド誘導体

Country Status (3)

Country Link
JP (1) JP2010120852A (ja)
TW (3) TW200840568A (ja)
WO (3) WO2008123017A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3078378A1 (en) 2015-04-08 2016-10-12 Vaiomer Use of factor xa inhibitors for regulating glycemia

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2197552B1 (en) * 2007-09-19 2012-11-21 4Sc Ag Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
EP2607348B8 (en) 2009-03-31 2021-04-21 Renascience Inc. Plasminogen Activator Inhibitor-1 Inhibitor
CN101875655B (zh) * 2009-04-28 2012-05-09 天津药物研究院 氨基苯甲酸衍生物及其制备方法和用途
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
KR20150105302A (ko) 2012-11-05 2015-09-16 난트 홀딩스 아이피, 엘엘씨 헤지 호그 신호 경로의 억제제로서 환상 술폰아미드 함유 유도체
EP2990057B1 (en) 2013-04-15 2019-03-20 Renascience Co., Ltd. Pai-1 inhibitor for use in enhancing the antitumor effect of an antitumor agent in a patient
CN106536520B (zh) 2014-06-27 2020-08-14 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
CA2954522A1 (en) 2014-07-07 2016-01-14 Acetylon Pharmaceuticals, Inc. Treatment of leukemia with histone deacetylase inhibitors
MX2017007623A (es) 2014-12-12 2018-09-26 Regenacy Pharmaceuticals Llc Derivados de piperidina como inhibidores de hdac1/2.
AU2016275764B8 (en) 2015-06-11 2021-03-04 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
ES2928856T3 (es) 2015-11-19 2022-11-23 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
UA126113C2 (uk) 2015-12-22 2022-08-17 Інсайт Корпорейшн Гетероциклічні сполуки як імуномодулятори
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017222976A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
SI3774791T1 (sl) 2018-03-30 2023-04-28 Incyte Corporation Heterociklične spojine kot imunomodulatorji
DK3790877T3 (da) 2018-05-11 2023-04-24 Incyte Corp Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer
KR102087080B1 (ko) * 2018-06-08 2020-03-10 주식회사 가피바이오 에독사반의 제조용 중간체의 제조 방법 및 에독사반의 제조 방법
JPWO2020153414A1 (ja) 2019-01-24 2021-12-02 武田薬品工業株式会社 複素環化合物及びその用途
CN113490623B (zh) * 2019-03-01 2023-06-16 三菱自动车工业株式会社 车辆用引擎盖
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
BR112022005826A2 (pt) 2019-09-30 2022-06-21 Incyte Corp Compostos de pirido[3,2-d]pirimidina como imunomoduladores
MX2022005651A (es) 2019-11-11 2022-07-27 Incyte Corp Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1).
KR102333564B1 (ko) * 2019-11-28 2021-12-01 동방에프티엘(주) 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
JP2023548859A (ja) 2020-11-06 2023-11-21 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤ならびにその塩及び結晶形態を作製するためのプロセス

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046569A1 (fr) * 1997-04-11 1998-10-22 Sumitomo Pharmaceuticals Co., Ltd. Derives de benzene
WO2001074791A1 (fr) * 2000-03-31 2001-10-11 Yamanouchi Pharmaceutical Co., Ltd. Derives de diazepane ou sels desdits composes
JP2004203791A (ja) * 2002-12-25 2004-07-22 Dai Ichi Seiyaku Co Ltd 芳香族化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ503809A (en) * 1997-12-19 2002-04-26 Schering Ag Ortho-anthranilamide derivatives as anti-coagulants
ES2260336T3 (es) * 2000-11-22 2006-11-01 Astellas Pharma Inc. Derivados de fenol sustituidos o sales de los mismos como inhibidores del factor de coagulacion x.
ATE368643T1 (de) * 2001-03-30 2007-08-15 Millennium Pharm Inc Faktor xa benzamidin inhibitoren
CA2460594A1 (en) * 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
JP2005097199A (ja) * 2003-09-26 2005-04-14 Tanabe Seiyaku Co Ltd アミン型カルボキサミド誘導体
WO2007007588A1 (ja) * 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046569A1 (fr) * 1997-04-11 1998-10-22 Sumitomo Pharmaceuticals Co., Ltd. Derives de benzene
WO2001074791A1 (fr) * 2000-03-31 2001-10-11 Yamanouchi Pharmaceutical Co., Ltd. Derives de diazepane ou sels desdits composes
JP2004203791A (ja) * 2002-12-25 2004-07-22 Dai Ichi Seiyaku Co Ltd 芳香族化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3078378A1 (en) 2015-04-08 2016-10-12 Vaiomer Use of factor xa inhibitors for regulating glycemia
WO2016162472A1 (en) 2015-04-08 2016-10-13 Vaiomer Use of factor xa inhibitors for regulating glycemia

Also Published As

Publication number Publication date
TW200843751A (en) 2008-11-16
WO2008111299A1 (ja) 2008-09-18
WO2008111300A1 (ja) 2008-09-18
TW200843752A (en) 2008-11-16
JP2010120852A (ja) 2010-06-03
TW200840568A (en) 2008-10-16

Similar Documents

Publication Publication Date Title
WO2008123017A1 (ja) 新規なジアミド誘導体
WO2008126901A1 (ja) 含窒素複素環化合物およびそれを含有する医薬組成物
WO2003063864A3 (fr) Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
TW200626598A (en) Pyrrazolo-pyrimidine derivatives
WO2005097129A3 (en) 6-azaindole compound
MX2010005299A (es) Derivados de bis-(sulfonilamino) en terapia 066.
EP1939175A4 (en) SULFONAMIDE DERIVATIVITY WITH PGD2 RECEPTOR ANTAGONISTIC EFFECT
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2008156094A1 (ja) ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
EP1864665A4 (en) IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
WO2008005368A3 (en) Piperazines as p2x7 antagonists
TW200642683A (en) Heterocyclic compound
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
WO2006071471A3 (en) 2-(2 or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
WO2009038064A1 (ja) Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する複素環誘導体
WO2009057784A1 (ja) 複素環化合物
WO2009051119A1 (ja) ピリミジルインドリン化合物
WO2009020137A1 (ja) アミノピラゾールアミド誘導体
WO2007017728A3 (en) Novel heterocyclic compounds
WO2008105058A1 (ja) スルホンアミド化合物
WO2008114812A1 (ja) Jak阻害剤
WO2008105526A1 (ja) マクロ環状化合物
HRP20090236T1 (en) Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof and the therapeutic application of the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08720392

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08720392

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP